| Stereochemistry | ABSOLUTE |
| Molecular Formula | C9H19NO2 |
| Molecular Weight | 173.2527 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC[C@@H](C)C[C@H](N)CC(O)=O
InChI
InChIKey=JXEHXYFSIOYTAH-SFYZADRCSA-N
InChI=1S/C9H19NO2/c1-3-4-7(2)5-8(10)6-9(11)12/h7-8H,3-6,10H2,1-2H3,(H,11,12)/t7-,8+/m1/s1
| Molecular Formula | C9H19NO2 |
| Molecular Weight | 173.2527 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Imagabalin is a ligand to the α(2)δ subunit of voltage-sensitive calcium channel and was developed to treat generalized anxiety disorder. Imagabalin was involved in phase III clinical trials when was made a decision to terminate all studies. However, this decision was not based on any safety concerns.
